This research not only elucidates how the aberrant expression of a metabolic enzyme can drive the crucial initial steps of tumor metastasis, but also establishes CPS1-mediated urea cycle reprogramming as a druggable metabolic vulnerability for combating metastatic disease. This evidence concerns the gene CPS1 and metastatic neoplasm.